Drug Development – Page 3

Boehringer Ingelheim Expands Oncology Pipeline via Strategic Collaboration with Tempus AI

5 months ago talkbio0Tagged Artificial Intelligence, Biological Markers, Boehringer Ingelheim, Cancer Research, Discover, Drug Development, Neoplasms, real-world data, strategic collaboration, Tempus AI

Boehringer Ingelheim; Tempus AI; oncology; cancer research; real-world data; AI; biomarker discovery; drug development; strategic collaboration

AbbVie Commits $335M Upfront in Landmark siRNA Deal With ADARx

5 months ago talkbio0Tagged AbbVie, ADARx, biotech partnerships, Drug Development, Gene Silencing, Immunology, Neoplasms, Neuroscience discipline, RNA technology, RNA, Small Interfering

AbbVie; ADARx Pharmaceuticals; siRNA therapeutics; gene silencing; neuroscience; immunology; oncology; biotech partnerships; RNA technology; drug development

GSK and iTeos End Belrestotug TIGIT Program After Disappointing Lung Cancer Results

5 months ago talkbio0Tagged belrestotug, Clinical Trials, dostarlimab, Drug Development, Galaxies, immuno-oncology, iTeos, Lung-201, Malignant neoplasm of lung, Progression-Free Survival, SmithKline Beecham, TIGIT gene

GSK; iTeos; belrestotug; TIGIT; lung cancer; dostarlimab; clinical trial; drug development; GALAXIES Lung-201; immuno-oncology; progression-free survival

Galapagos Reconsiders Company Split After Market Developments

5 months ago talkbio0Tagged Cell Therapy, Company Split, conditions, Drug Development, Galapagos, Leadership Change, Market, strategic review

Galapagos; company split; cell therapy; drug development; strategic review; leadership change; market conditions

Deerfield raises $600M healthcare fund to invest in therapeutics, AI

6 months ago talkbio0Tagged Artificial Intelligence, Deerfield, Drug Development, Health care facility, Investments

Deerfield, Artificial Intelligence, Investments, Drug Development, Health care facility

Novartis Halts Phase 2 Osteoarthritis Study of ADAMTS-5 Inhibitor Due to Lack of Pain Relief

6 months ago talkbio0Tagged ADAMTS-5, cartilage degradation, Clinical Trial Termination, Degenerative polyarthritis, Drug Development, Inhibitor, Knee pain, M6495, Novartis, Pain, QUC398

Novartis, phase 2 trial, osteoarthritis, knee pain, ADAMTS-5 inhibitor, QUC398, M6495, clinical trial termination, pain relief, cartilage degradation, drug development